SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

BACKGROUND: Tuberculosis household contacts are at elevated risk of HIV, and systematic screening for tuberculosis is an opportunity for people to know their status. We aimed to assess the coverage...

Key take-home messages

BACKGROUND: Human immunodeficiency virus (HIV) and other sexually transmitted infections (STI) are a major public health concern. Primary care (PC) is the ideal setting for their diagnosis. Designing effective strategies...

BACKGROUND: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) is a highly effective biomedical intervention for the prevention of HIV acquisition. There is a strong interest among communities and policymakers for LAI-PrEP scale-up,...

No abstract available

No abstract available

Despite substantial progress in expanding antiretroviral therapy (ART) coverage and scaling up prevention interventions, Human Immunodeficiency Virus (HIV) related mortality remains a significant public health challenge in several high-burden settings,...

BACKGROUND: As children living with HIV (CWH) achieve longer life expectancy, they face an emerging ‘double burden’ of infectious and non-communicable diseases, specifically pediatric overweight and obesity (OW/OB). This risk...

BACKGROUND: Long-acting antiretroviral therapy (LA-ART) is emerging as a promising strategy to enhance treatment satisfaction and improve the quality of life for people living with HIV (PLWH). A comprehensive understanding...

INTRODUCTION: Darunavir and lopinavir solid formulations are recommended protease inhibitors for treating HIV. An evidence review of their effectiveness/efficacy and safety in young populations was needed to inform the 2025...

BACKGROUND: People living with HIV (PLWH) face a significantly elevated risk of cardiovascular diseases (CVDs). This study aims to quantify temporal trends in HIV-attributable CVD burden at global, regional and...

BACKGROUND: Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor enabling treatment and prevention with reduced reliance on daily oral adherence. Evidence from randomized trials across indications remains fragmented. We systematically...